MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Depression"

  • 2019 International Congress

    Deep phenotyping adult onset isolated cervical dystonia; the importance of symptomatic anxiety and depression.

    I. Ndukwe, J. Dover, P. Lynch, F. O'Keeffe, S. O'Riordan, M. Hutchinson (Dublin, Ireland)

    Objective: Objective:We aimed to characterise the demographic and clinical aspects of cervical dystonia (CD) patients with symptomatic anxiety and depression. We hypothesised that these patients…
  • 2019 International Congress

    Efficacy and safety of the 5-Hydroxytryptophan on Depression and Apathy in Idiopathic Parkinson’s disease.

    M. Meloni, M. Puligheddu, M. Carta, M. Figorilli, G. Defazio (Cagliari, Italy)

    Objective: The purpose of this study was to compare the effects of 5-HTP to placebo on depression and apathy in patients with PD. Background: Parkinson’s…
  • 2019 International Congress

    Gender differences in Motor symptoms, Non-Motor symptoms and Quality of Life in Parkinson’s disease: COPPADIS-2015 study cohort

    M. Aguilar, P. Pastor, B. Solano, I. Cabo, MJ. Catalan, V. Nogueira, V. Puente, JM. Garcia, R. Perez, C. Borrué, M. Mata, M. Alvarez, AB. Rodriguez, L. Vela, Y. Macías, MJ. Marti, P. Martinez, D. Santos (Sabadell, Spain)

    Objective: To assess gender differences among PD patients and health controls (HC) of the COPPADIS-2015 study cohort. Background: Men and women are different in genetic,…
  • 2019 International Congress

    The effect of istradefylline on mood disorders in Parkinson’s disease

    H. Nagayama, O. Kano, H. Murakami, M. Hamada, R. Sengoku, Y. Shim, T. Toda (Tokyo, Japan)

    Objective: The effectiveness of istradefylline for treatment of mood disorders in patients with Parkinson's disease (PD) was examined in an open-label trial. Background: Depression is…
  • 2019 International Congress

    Open-Label Study of Pimavanserin Patients With Comorbid Parkinson’s Disease and Depression

    J. Norton, D. Fredericks, G. Alva, J. Aldred, B. Coate, D. Dekarske, M. Cantillon, R. Owen (San Deigo, CA, USA)

    Objective: We are assessing use of pimavanserin (PIM) for treatment of depression in adults with PD. Background: Depression occurs in ~50% of Parkinson’s disease (PD)…
  • 2019 International Congress

    The effects of zonisamide on motor and non-motor symptoms in patients with Parkinson’s disease: a 3-month open-label study

    K. Suzuki, H. Fujita, T. Matsubara, T. Kadowaki, K. Funakoshi, Y. Watanabe, T. Shiina, H. Sakuramoto, M. Hamaguchi, K. Hirata (Tochigi, Japan)

    Objective: To investigate the effect of zonisamide (ZNS) on motor and non-motor symptoms, such as depressive symptoms and sleep problems, in patients with Parkinson’s disease…
  • 2019 International Congress

    Higher levels of physical activity is associated with fewer non-motor symptoms in early Parkinson’s disease: a 1-year follow-up study

    S. Ng, N. Chia, M. Abbas, KY. Tay, WL. Au, EK. Tan, L. Tan (Singapore, Singapore)

    Objective: To examine the physical activity (PA) level in early Parkinson’s disease (PD) patients and its association with non-motor symptoms (NMS). Background: Lower PA is…
  • 2019 International Congress

    Vortioxetine treatment of depression in Parkinson’s disease

    M. Russo, C. Carrarini, F. Dono, L. Ferri, M. Di Pietro, M. Onofrj (Chieti, Italy)

    Objective: To assess efficacy and safety of Vortioxetine in Parkinson’s Disease (PD) patients affected by depression and its effects on motor performance. Background: Depression is…
  • 2019 International Congress

    Impact of a high-fat diet on the behavior of A53T alpha-Synuclein Parkinson’s disease mice

    M. Temmel, V. Niederkofler, R. Rabl, H. Roemer, B. Hutter-Paier (Grambach, Austria)

    Objective: The aim of this project was to evaluate high-fat diet (HFD) induced behavioral alterations in the A53T alpha-Synuclein Parkinsons’s disease mouse model. Background: Besides…
  • 2019 International Congress

    Influence of Cognitive Deficits and Tremor Severity of the Development of Depression in Nondemented Patients with Essential Tremor

    M. Petrova, O. Grigorova, M. Raycheva, L. Traykov (Sofia, Bulgaria)

    Objective: The aim of this study was to investigate the relationship between cognitive deficits and tremor severity with the development of depression in nondemented ET…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 36
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley